Citations

Clear

2960 citation(s) found for "Kim, P".

Mesorectal Fascial Involvement in Rectal Cancer
Horvat, Natally , Kim, Tae‐Hyung , Horvat, Natally

Mayo Clinic

Radiology | October 28, 2025 | Volume: 317 | Issue: 1 | Pages: No page available

10.1148/radiol.253086 | PMID 41147909 Get It

Compromised pressure-generating capacity of diaphragmatic muscle and its interaction with the lower rib cage at high lung volume during airway occlusion
Boriek, Aladin M. , Rodriguez-Santiago, Noralis, Kim, Sanghyun , Wynd, Shari , Hubmayr, Rolf D., Kim, Sanghyun , Ford, Aubri

Mayo Clinic

American Journal of Physiology-Regulatory, Integrative and Comparative Physiology | October 24, 2025 | Volume: 329 | Issue: 6 | Pages: R959-R971

10.1152/ajpregu.00080.2025 | PMID 41134675 Get It

Data from the current study support the hypothesis that the pressure-generating capacity of the diaphragm at high lung volume is compromised primarily due to a mechanism that involves a combined mechanical effect of hyperinflation and substantial muscle contraction rather than a significant loss of its muscle fiber curvature.
Cost-Effectiveness and Evidence Gaps Surrounding PSMA-PET for Recurrent Prostate Cancer Evaluation
Long, Jessica B., Sprenkle, Preston C. , Kim, Isaac Yi , Saperstein, Lawrence, Rabil, Maximilian , Ghaffar, Umar , Karnes, R. Jeffrey , Ma, Xiaomei , Gross, Cary P. , Leapman, Michael S., Kunst, Natalia , Wang, Shi‐Yi

Mayo Clinic

JAMA Network Open | October 24, 2025 | Volume: 8 | Issue: 10 | Pages: e2539250

10.1001/jamanetworkopen.2025.39250 | PMID 41134573 Get It

Importance Prostate-specific membrane antigen positron emission tomography (PSMA-PET), a form of molecular imaging, increases detection of advanced and metastatic prostate cancer, but its potential to increase treatment costs due to increased detection is poorly defined. Objective To estimate lifetime health and cost outcomes and evaluate the cost-effectiveness associated with implementing PSMA-PET in the clinical evaluation of a patient with a biochemical recurrence (BCR) of prostate cancer, with evaluation of sources of uncertainty in the underlying evidence and assessment of the need and focus of additional data collection. Design, Setting, and Participants This economic evaluation developed a decision-analytic model consisting of a decision tree and a Markov model informed by published literature and a study of patients with BCR prostate cancer undergoing PSMA-PET after definitive surgery or radiation therapy at 2 high-volume US academic centers. The analysis was performed between August 1, 2024, and May 1, 2025. Interventions Patients underwent (1) PSMA-PET, (2) PSMA-PET imaging as a reflex test if computed tomography plus bone scan (CTBS) was negative or equivocal (CTBS + PSMA-PET), and (3) CTBS alone. Main Outcomes and Measures Lifetime quality-adjusted life-years (QALYs) and costs, incremental cost-effectiveness ratio (ICER), and value of information estimates were assessed, with 95% uncertainty intervals (UIs). We assumed a willingness-to-pay threshold of $150 000 per QALY. Results The model simulated 1000 patients with BCR (median age, 66 years) and estimated that up-front PSMA-PET is expected to have the highest mean QALYs (7.12 QALYs [95% UI, 6.71-7.51 QALYs]) compared with 6.55 QALYs (95% UI, 6.08-7.03 QALYs) for CTBS; it was also estimated to have higher mean costs ($451 000 [95% UI, $336 000-$577 000]) compared with $351 000 (95% UI, $263 000-$455 000]) for CTBS; consequently, PSMA-PET had mean increments of $99 000 (95% UI, $55 000-153,000) in costs and 0.58 QALYs (95% UI, 0.35-0.82 QALYs) compared with CTBS, leading to an ICER of $172 000 per QALY, which exceeded the assumed $150 000/QALY willingness-to-pay threshold. In patients with lower prostate-specific antigen levels (<2 ng/mL), PSMA had mean increments of $61 000 (95% UI, $21 000-$104 000) in costs and 0.54 QALYs (95% UI, 0.34-0.77 QALYs) compared with CTBS, leading to an ICER of $113 000/QALY, suggesting it had the potential to be cost-effective. Because of high decisional uncertainty, additional information regarding outcomes and diagnostic characteristics may be associated with reduced uncertainty and a gain of 15 747 QALYs. Conclusions and Relevance This study found that PSMA-PET may be associated with improved disease detection but may not be cost-effective due to high treatment costs offsetting moderate improvements in QALYs. Further research is needed to identify patient subsets and clinical scenarios in which molecular imaging provides the greatest value.
Genome-wide association studies identify 77 loci for suicidality and provide novel biological insights
Colbert, Sarah M. C. , Koromina, Maria, Hatoum, Alexander S, Stephenson, Mallory, Edwards, Alexis C, Johnson, Emma C, Qin, Xuejun, Shabalin, Andrey A, Ito, Lucas T, O’Connell, Kevin S, Harder, Arvid, Hjerling-Leffler, Jens, Kim, Min Ji, Otsuka, Ikuo, Vilar-Ribó, Laura, Agrawal, Arpana, Alda, Martin, Alfredsson, Lars, Aliev, Fazil, Andlauer, Till FM, Arango, Celso, Arntz, Arnoud, Awasthi, Swapnil, Ayinde, Olatunde O, Bacanu, Silviu-Alin, Barr, Peter B, Bau, Claiton HD, Baune, Bernhard T, Beckham, Jean C, Bejan, Cosmin A, Belangero, Sintia, Berger, Klaus, Biernacka, Joanna M, Bogdan, Ryan, Boomsma, Dorret I, Børglum, Anders D, Bourassa, Kyle J, Braff, David L, Braun, Alice, Bressan, Rodrigo A, Brueckl, Tanja M, Budde, Monika, Cabrera-Mendoza, Brenda, Carpiniello, Bernardo, Ceja, Zuriel, Cervilla, Jorge A, Chang, Chiao-Erh, Chaumette, Boris, Cheon, Myeong Jae, Cichon, Sven, Coleman, Jonathan RI, Coon, Hilary, Copeland, William E, Czamara, Darina, Dalkner, Nina, Dannlowski, Udo, David, Friederike S, Demontis, Ditte, Florio, Arianna Di, Diaconu, Carmen C, Dick, Danielle M, Dikeos, Dimitris, Djurovic, Srdjan, Edenberg, Howard J, Erlangsen, Annette, Euler, Sebastian, Falkai, Peter, Fanelli, Giuseppe, Fellendorf, Frederike T, Ferentinos, Panagiotis, Fernandez-Aranda, Fernando, Forstner, Andreas J, Frei, Oleksandr, Fries, Gabriel R, Fullerton, Janice M, Gaine, Marie E, Galfalvy, Hanga C, Galimberti, Marco, Garcia-Aymerich, Judith, Garrett, Melanie E, Gawlik, Micha, Gelernter, Joel, Gordon-Smith, Katherine, Gorelik, Aaron J, Gorwood, Philip, Grabe, Hans J, Green, Melissa J, Grigoroiu-Serbanescu, Maria, Gupta, Priya, Gutiérrez, Blanca, Guzman-Parra, Jose, Han, Seonggyun, Haram, Marit, Hauser, Elizabeth R, Heilbronner, Urs, Herpertz, Sabine C, Herrera-Imbroda, Jesús, Hesselbrock, Victor M, Hishimoto, Akitoyo, Holla, Bharath, Izotova, Anastasia, Jang, Yoonjeong, Jimenez-Murcia, Susana, Jones, Lisa A, Jonsson, Lina, Kang, JooEun, Kang, Joon Ho, Keel, Pamela K, Kim, Jaeyoung, Kim, Dongjun, Kircher, Tilo, Kirov, George, Kraft, Julia, Kramer, John, Kranzler, Henry R, Kuo, Po-Hsiu, Kurvits, Siim, Lai, Dongbing, Lake, Marilyn T, Landén, Mikael, Lannoy, Séverine, Law, Matthew H, Lee, Byung-Chul, Lee, Young Kee, Lehto, Kelli, Levey, Daniel F, Lewis, Cathryn M, Li, Qingqin S, Liao, Calwing, Lind, Penelope A, Lochner, Christine, Lori, Adriana, Maes, Hermine HM, Mahadevan, Jayant, Manchia, Mirko, Mars, Becky, Martin, Nicholas G, Martorell, Lourdes, McIntosh, Andrew M, McMain, Shelley F, McQuillin, Andrew, Medland, Sarah E, Mitchell, Philip B, Molina, Esther, Monson, Eric T, Mufford, Mary S, Muntané, Gerard, Musil, Richard, Myung, Woojae, Neagu, Ana Iulia, Nielsen, Trine T, Nöthen, Markus M, Nunez, Yaira Z, Nurnberger, John I, Okazaki, Satoshi, Olsen, Catherine M, Ophoff, Roel A, Owen, Michael J, Pan, Pedro M, Papiol, Sergi, Pascual, Juan C, Patrinos, George P, Pawlak, Joanna M, Penninx, Brenda WJH, Pérez-Gutiérrez, Ana M, Perroud, Nader, Peterson, Roseann E, Pisanu, Claudia, Pistis, Giorgio, Porjesz, Bernice, Posthuma, Danielle, Powers, Abigail, Preisig, Martin, Purushottam, Meera, Reif, Andreas, Reininghaus, Eva Z, Rentería, Miguel E, Ripke, Stephan, Ripperger, Michael A, Rivera, Margarita, Roberts, Emily K, Roberts, Gloria, Rødevand, Linn, Roepke, Stefan, Rovaris, Diego L, Salum, Giovanni A, Sanders, Alan R, Santoro, Marcos L, Sawyers, Chelsea, Scherer, Stephen W, Schilling, Claudia, Schmahl, Christian, Schofield, Peter R, Schulze, Thomas G, Scott, Laura J, Serretti, Alessandro, Shadrin, Alexey, Shirai, Toshiyuki, Smeland, Olav B, Smoller, Jordan W, Sokolowski, Marcus, Sonuga-Barke, Edmund J, Squassina, Alessio, Starnawska, Anna, Steen, Nils Eiel, Stein, Dan J, Stein, Frederike, Stein, Murray B, Streit, Fabian, Sud, Reeteka, Sullivan, Patrick F, Terao, Chikashi, Toma, Claudio, Tondo, Leonardo, Turecki, Gustavo, Uher, Rudolf, Ursano, Robert J, Auwera, Sandra Van der, Vawter, Marquis P, Paska, Alja Videtic, Vilella, Elisabet, Vincent, John B, Viswanath, Biju, Vladimirov, Vladimir, Wasserman, Danuta E, Weickert, Thomas W, Whiteman, David C, Willour, Virginia L, Wiström, Erik D, Witt, Stephanie H, Won, Hong-Hee, Wootton, Robyn E, Zai, Clement C, Zhang, Jian, Zillich, Lea, MGL, CVEDA and, Andreassen, Ole A, Palmer, Abraham A, Sanchez-Roige, Sandra, Mann, J John, Kimbrel, Nathan A, Ashley-Koch, Allison E, Docherty, Anna R. , Mullins, Niamh , Roberts, Gloria , Pisanu, Claudia , Holla, Bharath , Fanelli, Giuseppe , Ruderfer, Douglas , Docherty, Anna R , Mullins, Niamh , Pisanu, Claudia , Koromina, Maria, Hatoum, Alexander S, Stephenson, Mallory, Edwards, Alexis C, Johnson, Emma C, Qin, Xuejun, Shabalin, Andrey A, Ito, Lucas T, O’Connell, Kevin S, Harder, Arvid, Hjerling-Leffler, Jens, Kim, Min Ji, Otsuka, Ikuo, Vilar-Ribó, Laura, Agrawal, Arpana, Alda, Martin, Alfredsson, Lars, Aliev, Fazil, Andlauer, Till FM, Arango, Celso, Arntz, Arnoud R. , Awasthi, Swapnil, Ayinde, Olatunde O, Bacanu, Silviu-Alin, Barr, Peter B, Bau, Claiton HD, Baune, Bernhard T, Beckham, Jean C, Bejan, Cosmin A, Belangero, Sintia, Berger, Klaus, Biernacka, Joanna M, Bogdan, Ryan, Boomsma, Dorret I , Børglum, Anders D, Bourassa, Kyle J, Braff, David L, Braun, Alice, Bressan, Rodrigo A, Brueckl, Tanja M, Budde, Monika, Cabrera-Mendoza, Brenda, Carpiniello, Bernardo, Ceja, Zuriel, Cervilla, Jorge A, Chang, Chiao-Erh, Chaumette, Boris , Cheon, Myeong Jae, Cichon, Sven, Coleman, Jonathan RI, Coon, Hilary, Copeland, William E, Czamara, Darina, Dalkner, Nina, Dannlowski, Udo, David, Friederike S, Demontis, Ditte, Florio, Arianna Di, Diaconu, Carmen C, Dick, Danielle M, Dikeos, Dimitris, Djurovic, Srdjan, Edenberg, Howard J, Erlangsen, Annette , Euler, Sebastian, Falkai, Peter , Fellendorf, Frederike T, Ferentinos, Panagiotis, Fernandez-Aranda, Fernando, Forstner, Andreas J, Frei, Oleksandr, Fries, Gabriel R, Fullerton, Janice M, Gaine, Marie E, Galfalvy, Hanga C, Galimberti, Marco, Garcia-Aymerich, Judith, Garrett, Melanie E, Gawlik, Micha, Gelernter, Joel, Gordon-Smith, Katherine, Gorelik, Aaron J, Gorwood, Philip , Grabe, Hans J, Green, Melissa J, Grigoroiu-Serbanescu, Maria, Gupta, Priya, Gutiérrez, Blanca, Guzman-Parra, Jose, Han, Seonggyun, Haram, Marit, Hauser, Elizabeth R, Heilbronner, Urs , Herpertz, Sabine C, Herrera-Imbroda, Jesús, Hesselbrock, Victor M, Hishimoto, Akitoyo, Izotova, Anastasia, Jang, Yoonjeong, Jimenez-Murcia, Susana, Jones, Lisa A, Jonsson, Lina, Kang, JooEun, Kang, Joon Ho, Keel, Pamela K, Kim, Jaeyoung, Kim, Dongjun, Kircher, Tilo, Kirov, George, Kraft, Julia, Kramer, John, Kranzler, Henry R, Kuo, Po-Hsiu, Kurvits, Siim, Lai, Dongbing, Lake, Marilyn T, Landén, Mikael, Lannoy, Séverine, Law, Matthew H, Lee, Byung-Chul, Lee, Young Kee, Lehto, Kelli, Levey, Daniel F, Lewis, Cathryn M, Li, Qingqin S, Liao, Calwing, Lind, Penelope A, Lochner, Christine, Lori, Adriana, Maes, Hermine HM, Mahadevan, Jayant, Manchia, Mirko, Mars, Becky, Martin, Nicholas G, Martorell, Lourdes, McIntosh, Andrew M, McMain, Shelley F, McQuillin, Andrew, Medland, Sarah E, Mitchell, Philip B, Molina, Esther, Monson, Eric T, Mufford, Mary Sophia , Muntané, Gerard, Musil, Richard, Myung, Woojae, Neagu, Ana Iulia, Nielsen, Trine T, Nöthen, Markus M, Nunez, Yaira Z, Nurnberger, John I, Okazaki, Satoshi, Olsen, Catherine M, Ophoff, Roel A. , Owen, Michael J, Pan, Pedro M, Papiol, Sergi, Pascual, Juan C, Patrinos, George P, Pawlak, Joanna M, Penninx, Brenda WJH, Pérez-Gutiérrez, Ana M, Perroud, Nader, Peterson, Roseann E, Pistis, Giorgio, Porjesz, Bernice, Posthuma, Danielle, Powers, Abigail, Preisig, Martin, Purushottam, Meera, Reif, Andreas, Reininghaus, Eva Z, Rentería, Miguel E, Ripke, Stephan, Ripperger, Michael A, Rivera, Margarita, Roberts, Emily K, Roberts, Gloria, Rødevand, Linn, Roepke, Stefan, Rovaris, Diego L, Salum, Giovanni A, Sanders, Alan R, Santoro, Marcos L, Sawyers, Chelsea, Scherer, Stephen W, Schilling, Claudia, Schmahl, Christian, Schofield, Peter R, Schulze, Thomas , Scott, Laura J, Serretti, Alessandro, Shadrin, Alexey, Shirai, Toshiyuki, Smeland, Olav B, Smoller, Jordan W, Sokolowski, Marcus , Sonuga-Barke, Edmund J, Squassina, Alessio, Starnawska, Anna, Steen, Nils Eiel, Stein, Dan J, Stein, Frederike, Stein, Murray B, Streit, Fabian, Sud, Reeteka, Sullivan, Patrick F, Terao, Chikashi, Toma, Claudio, Tondo, Leonardo, Turecki, Gustavo, Uher, Rudolf, Ursano, Robert J, Auwera, Sandra Van der, Vawter, Marquis P, Paska, Alja Videtic, Vilella, Elisabet, Vincent, John B, Viswanath, Biju, Vladimirov, Vladimir, Wasserman, Danuta E, Weickert, Thomas W, Whiteman, David C, Willour, Virginia L, Wiström, Erik D, Witt, Stephanie H, Won, Hong-Hee, Wootton, Robyn E, Zai, Clement C, Zhang, Jian, Zillich, Lea, MGL, CVEDA and, Andreassen, Ole A, Palmer, Abraham A, Sanchez-Roige, Sandra, Mann, J John, Kimbrel, Nathan A, Ashley-Koch, Allison E

Mayo Clinic

No container title available | October 23, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.10.22.25338076 | PMID 41282879 Get It

ABSTRACT Suicidality contributes substantially to global morbidity and mortality, yet despite its heritability, its biological etiology remains largely elusive. We conducted multi-ancestry genome-wide association study meta-analyses of suicidal ideation (259,747 cases), suicide attempt (64,993 cases), suicide death (9,197 cases), and suicidal behavior (suicide attempt/ death, 75,300 cases), across 54 cohorts (e.g., the Psychiatric Genomics Consortium, Million Veteran Program, UK Biobank). We identified 77 significant loci across meta-analyses, including 59 previously unreported for suicidality. SNP-based heritability ranged from 2.0-6.7% and there were strong, yet incomplete, genetic correlations between suicidality phenotypes (0.70-0.88). Fine-mapping prioritized putative causal SNPs and 20 credible genes. Enrichment analyses implicated synaptic pathways and neuronal populations predominantly in subcortical brain regions (e.g., amygdala excitatory, medium spiny, hippocampal CA1-3). Together, these findings establish suicidality as a polygenic set of traits with both shared and distinct genetic influences, providing a foundation for future studies of suicide biology and etiology.
Circulating cell‐free DNA methylation biomarkers for hepatocellular carcinoma risk prediction in HIV ‐positive Nigerian population
Zheng, Yinan , Han, Jingzhe , Qu, Yishu , Wang, Jun , Okeke, Edith, Davwar, Pantong , Duguru, Mary, Nyam, David, Oyeleke, Ganiyat K. , Sulaimon, Akanmu A., Hawkins, Claudia , Badmos, Kabir, Gursel, Demirkan, Silas, Olugbenga A. , Kocherginsky, Masha , Sun, Zequn , Achenbach, Chad J. , Yang, Hushan , Sagay, Atiene S. , Roberts, Lewis R., Hou, Lifang , Roberts, Lewis R. , Yang, Hushan , Roberts, Lewis R , Zheng, Yinan , Hou, Lifang , Wang, Jun , Joyce, Brian , Odeghe, Emuobor , Lesi, Olufunmilayo , Imade, Godwin , Abdulkareem, Fatimah Biade , Wei, Jian‐Jun , Kim, Kwang‐Youn A. , Zhang, Xuehong , Ogunsola, Folasade Tolulope , Murphy, Robert L. , Roberts, Lewis R.

Mayo Clinic

International Journal of Cancer | October 23, 2025 | Volume: 158 | Issue: 5 | Pages: 1281-1291

10.1002/ijc.70204 | PMID 41129333 Get It

Abstract Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality globally, with particularly high burdens among people living with HIV (PLWH) in low‐resource settings like Nigeria. Effective early detection remains a major challenge due to limited access to imaging‐based surveillance and the low sensitivity of current biomarkers such as alpha‐fetoprotein (AFP). We conducted an epigenome‐wide association study (EWAS) of circulating cell‐free DNA (ccfDNA) methylation in a Nigerian cohort of HIV‐positive individuals ( n = 245), spanning HCC, cirrhosis (FibroScan ≥12.3 kPa), fibrosis (FibroScan ≥7.6 and <12.3 kPa), and HCC‐free without fibrosis (FibroScan <7.6 kPa) groups. Using random forest modeling, we developed and evaluated a ccfDNA methylation classifier (ccfDNAmRF) for HCC risk prediction. We identified 73 CpG sites significantly associated with HCC (false discovery rate <0.01). The ccfDNAmRF model demonstrated strong discriminatory power, achieving 100% sensitivity and 80%–91% specificity for distinguishing HCC from cirrhosis, fibrosis, and HCC‐free groups (area under the curve [AUC]: 92%–97%). Combining ccfDNA methylation risk scores with AFP further improved classification accuracy (AUC up to 98.5%). Notably, ccfDNA methylation patterns displayed clear dose–response relationships across the disease spectrum, supporting their utility for early‐stage detection and risk stratification. Our findings highlight the promise of ccfDNA methylation biomarkers as a non‐invasive, blood‐based screening tool for improving early identification of HCC cases among PLWH.
Antibiotic Exposure and Cardiovascular Disease Risk: A Nationwide Cohort Study
Park, Sun Jae , Kim, Minseo , Jeong, Seogsong , Choi, Seulggie , Kim, Hye Jun , Song, Jihun, Lee, Jaewon, Lee, Ji Won, Jeong, Jihui, Yu, Jiwon , Park, Young Jun , Kim, Hye Jun , Choi, Jiwon , Chang, Jooyoung , Oh, Yun Hwan , Ahn, Joseph C , Park, Sang Min , Lee, Ji‐Won , Chang, Jooyoung , Ahn, Joseph , Park, Sang Min

Mayo Clinic

Journal of the American Heart Association | October 22, 2025 | Volume: 14 | Issue: 20 | Pages: No page available

10.1161/jaha.124.035888 | PMID 41120818 Get It

Background Antibiotic use may alter gut microbiota, which could be associated with various diseases, including cardiovascular disease (CVD). Accordingly, further epidemiological evidence is needed to clarify the potential risk of CVD associated with antibiotic exposure. We evaluated the association between long‐term antibiotic exposure and CVD risk in South Korea. Methods and Results This nationwide retrospective cohort study used data from the Korean National Health Insurance Service database. A total of 2 159 965 individuals aged 40 to 79 years who had no history of antibiotic prescriptions from 2004 to 2005 were included and followed through December 31, 2021. Antibiotic exposure was defined as the cumulative days of antibiotic prescriptions from 2006 to 2010. The primary end point was incident CVD with 2 or more days of hospitalization from 2011 to 2021. Adjusted hazard ratios (aHR) and 95% CIs for CVD according to antibiotic exposure were estimated using multivariable Cox proportional hazards models, adjusting for a range of covariates. Longer cumulative antibiotic prescription days were associated with an increased risk of CVD. The aHRs for CVD associated with 1 to 14, 15 to 90, 91 to 180, 181 to 364, and ≥365 days of antibiotic exposure were 0.98 (95% CI, 0.96–1.01), 1.01 (95% CI, 0.99–1.03), 1.05 (95% CI, 1.03–1.08), 1.06 (95% CI, 1.04–1.09), and 1.10 (95% CI, 1.07–1.13) compared with those with no antibiotic prescriptions. Conclusions In this large population‐based cohort study of Korean adults, long‐term antibiotic exposure may be associated with a higher risk of CVD. Further research is warranted to establish causality and elucidate the underlying mechanisms for this association.
What Is Clinical Anatomy?—A Consensus Statement From the American Association of Clinical Anatomists
Rajaram‐Gilkes, Mathangi, Chaiyamoon, Arada , Ezra, David , Raoof, Ameed , Rae, Guenevere , Mtui, Estomih P., Detton, Alan J., Anand, Mahindra , Raeburn, Kazzara , Kim, Hee‐Jin , Sekhar, Laligam N., Watanabe, Koichi , D’Antoni, Anthony V. , Loukas, Marios , Spinner, Robert J. , Tubbs, R. Shane, Iwanaga, Joe , Ezra, David , Rae, Guenevere , Kim, Hee-Jin , Watanabe, Koichi , Antoni, Anthony D' , Loukas, Marios , Spinner, Robert J , Adds, Philip , Iwanaga, Joe , Bubb, Kathleen , Rajaram-Gilkes, Mathangi, Noël, Geoffroy P. J. C. , Hur, Mi-Sun , Sekhar, Laligam N. , Tabira, Yoko , Khalil, Mohammed K. , Adds, Philip J.

Mayo Clinic

Clinical Anatomy | October 21, 2025 | Volume: 39 | Issue: 1 | Pages: 72-76

10.1002/ca.70040 | PMID 41117176 Get It

ABSTRACT At the 42nd Annual Meeting of the American Association of Clinical Anatomists (AACA) in Bellevue, Washington, June 2025, two inaugural events—the Clinical Anatomy Fireside Chat (CAFC) and the Clinical Anatomy Symposium: Head and Neck 2025 (CAS)—fostered rich dialogue on the evolving role and operational definition of clinical anatomy. Experts from various clinical and anatomical disciplines explored the meaning of clinical anatomy, highlighting the absence of a universal definition despite its frequent use in education and research. Through these interdisciplinary discussions, a consensus emerged: clinical anatomy is not defined solely by the possession of clinical credentials but by the integration of anatomical knowledge and clinical relevance, achieved most effectively through collaboration. Clinical anatomy education and research require different depths of clinical knowledge depending on the audience and objective, and meaningful collaboration can bridge gaps in expertise. The symposium further illustrated that high‐quality clinical anatomy emerges from mutual respect and reciprocal insight between clinicians and anatomists. This article presents a consensus statement developed by AACA representatives and invited speakers, affirming that collaboration is not only foundational to the practice of clinical anatomy but also fundamental to its definition. These conclusions aim to guide future educational models, research strategies, and interdisciplinary partnerships in the field of clinical anatomy.
African and Hispanic Americans Have Higher Healthcare-Related Burden Without Higher Mortality When Admitted with Acute Diverticulitis
Nieto, Luis M. , Narvaez, Sharon I., Kim, Do Han , Ko, Donghyun , Lukens, Frank , Palacios-Argueta, Pedro, Vega, Kenneth J. , Kim, Do Han , Ko, Donghyun

Mayo Clinic

Gastroenterology Insights | October 21, 2025 | Volume: 16 | Issue: 4 | Pages: 40

10.3390/gastroent16040040 Get It

Background: Health disparities between racial groups continue to exist. There is a paucity of data regarding presentation severity for acute diverticulitis (AD) and surgery need by race. This study’s aim was to evaluate outcomes of AD in United States racial groups. Methods: A retrospective cohort study was performed using the 2016–2019 National Inpatient Sample of adult patients discharged for AD. Patients were classified into six racial and ethnic groups: Caucasian, African American (AA), Hispanic, Asian, Native American (NA), and other. Multivariate regression analysis adjusted for patient and hospital characteristics was performed for primary and secondary outcomes. Results: A total of 647,119 admissions with acute diverticulitis (AD) were identified. Most patients were Caucasian (about three-quarters), followed by Hispanics (11%), AA (9%), Asians (1%), Native Americans (<1%), and other (2%). Minority groups were generally younger than Caucasians and less likely to undergo colonoscopy or surgical procedures such as partial or total colectomy. In the multivariable analysis, both Hispanics and AA were less likely to present with complicated diverticulitis. Despite this, their hospitalizations were associated with higher overall charges and costs. No significant differences were found across groups in terms of inpatient mortality or the need for percutaneous abscess drainage. Conclusions: Hispanic and AA have higher healthcare- related charges and costs compared to Caucasians when admitted with AD. Further studies are needed to understand the healthcare-related spending variations seen in these groups despite them often having less complicated AD.
Standalone Endovascular Embolization versus Stereotactic Radiosurgery in the Treatment of Arteriovenous Malformations in Eloquent Brain
Musmar, Basel , Abdalrazeq, Hammam , Adeeb, Nimer , Salim, Hamza , Roy, Joanna M. , Aslan, Assala , Tjoumakaris, Stavropoula I., Ogilvy, Christopher S. , Başkaya, Mustafa K. , Kondziolka, Douglas, Sheehan, Jason P. , Riina, Howard A. , Abushehab, Abdallah, Naamani, Kareem El, Ironside, Natasha , Gummadi, Sanjeev, Ataoglu, Cagdas , Muram, Sandeep , Sconzo, Daniel , Rezai, Arwin, Alwakaa, Omar , Park, Min S. , Hanalıoğlu, Şahin , Erginoğlu, Ufuk , Sen, Rajeev , Burkhardt, Jan‐Karl , Starke, Robert M. , Sekhar, Laligam N., Altschul, David , Haranhalli, Neil , McAvoy, Malia , Zeineddine, Hussein A. , Atallah, Elias , Rosenwasser, Robert H. , Stapleton, Christopher J. , Koch, Matthew J. , Srinivasan, Visish M. , Bulsara, Ketan R., Kim, Louis J. , Pukenas, Bryan, Smith, Edward R. , Alaraj, Ali , Patel, Aman B. , Notarianni, Christina , Lawton, Michael, Guthikonda, Bharat , Salim, Hamza , Riina, Howard , Dmytriw, Adam A , Gummadi, Sanjeev , Ataoglu, Cagdas , Essibayi, Muhammed Amir , Keles, Abdullah , Muram, Sandeep , Alwakaa, Omar , Mantziaris, Georgios , Park, Min S , Hanalioglu, Sahin , Erginoglu, Ufuk , Pöppe, Johannes , Griessenauer, Christoph J , Starke, Robert M , Levitt, Michael R , Altschul, David J , Haranhalli, Neil , Zeineddine, Hussein A , Atallah, Elias , Stapleton, Christopher , Koch, Matthew J , Srinivasan, Visish M , Chen, Peng R , Blackburn, Spiros , Bulsara, Ketan , Choudhri, Omar , Pukenas, Bryan , Smith, Edward , Alaraj, Ali , Patel, Aman B , Notarianni, Christina , Jabbour, Pascal , Musmar, Basel , Ogilvy, Christopher S , Tjoumakaris, Stavropoula , Kandregula, Sandeep , Dmytriw, Adam A. , Naamani, Kareem El , Abdelsalam, Ahmed , Kumbhare, Deepak , Essibayi, Muhammed Amir , Keleş, Abdullah , Tos, Salem M , Mantziaris, Georgios , Sen, Rajeev D., Griessenauer, Christoph J. , Sekhar, Laligam N. , Levitt, Michael R. , Abla, Adib A. , Gooch, Michael Reid , Kim, Louis J. , Choudhri, Omar , Pukenas, Bryan , Mosimann, Pascal J , Aziz‐Sultan, Mohammad Ali , Savardekar, Amey Rajan , Cuellar, Hugo , Morcos, Jacques J. , Jabbour, Pascal

Mayo Clinic

Radiology | October 21, 2025 | Volume: 317 | Issue: 1 | Pages: No page available

10.1148/radiol.250329 | PMID 41117652 Get It

Stereotactic radiosurgery was associated with a higher obliteration rate compared with embolization in patients with eloquent brain arteriovenous malformations, whereas there was no evidence of a difference in functional outcomes or complications after adjustment.
Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease
Lu, Ming , Collins, Emily C. , Shcherbinin, Sergey, Ellinwood, Amy K., Brooks, Dawn A. , Knopman, David S., Sims, John R. , Mintun, Mark A., Kim, Min Jung , Ellinwood, Amy K. , Yokoi, Yuma , Hansson, Oskar

Mayo Clinic

JAMA Neurology | October 13, 2025 | Volume: 82 | Issue: 12 | Pages: 1251

10.1001/jamaneurol.2025.3869 | PMID 41082199 Get It

Importance Accumulation of amyloid plaque drives pathogenesis of Alzheimer disease (AD). Reduction of amyloid via amyloid-targeting therapies may result in clinical benefit. Objective To assess the correlation of posttreatment amyloid levels with clinical outcomes and biomarkers in AD. Design, Setting, and Participants This was a post hoc exploratory analysis from the randomized, placebo-controlled phase 3 trial, TRAILBLAZER-ALZ 2, conducted June 2020 through April 2023 at 277 medical research centers/hospitals in 8 countries. A total of 8240 participants aged 60 to 85 years with early symptomatic AD with amyloid and tau pathology based on positron emission tomography (PET) imaging were assessed for eligibility. Of these, 6504 participants were excluded predominantly due to inadequate amyloid or tau pathology. The current analysis included 1582 participants (766 in the donanemab group and 816 in the placebo group) with baseline and at least 1 posttreatment assessment. Data analysis took place from July 2024 to March 2025. Interventions Participants were randomized 1:1 to receive donanemab (700 mg for the first 3 doses and 1400 mg thereafter) or placebo intravenously every 4 weeks for up to 72 weeks, with outcomes assessed through 76 weeks. Main Outcomes and Measures Participants were categorized into 1 of 10 groups (deciles) based on their lowest amyloid value observed posttreatment. Clinical progression was assessed via changes in integrated Alzheimer’s Disease Rating Scale (iADRS) and Clinical Dementia Rating–Sum of Boxes (CDR-SB) scores. Plasma biomarkers measured included phosphorylated tau 217 (p-tau217), p-tau181, glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL). Correlations between the median amyloid level in each decile were assessed with 76-week least-squares mean changes in each outcome and biomarker. Results Analyses included 1582 participants, including 766 treated with donanemab and 816 with placebo. The mean (SD) age was 72.9 (6.2) years, and 900 participants (56.9%) were female. Participants who received donanemab had lower posttreatment amyloid values than those in the placebo group. Across the trial population, lower posttreatment amyloid levels were correlated with slower clinical progression as measured by iADRS score ( R 2 , 0.73 [95% CI, 0.37-0.97]) and CDR-SB score ( R 2 , 0.87 [95% CI, 0.70-0.97]) and with decreases in p-tau217 ( R 2 , 0.86 [95% CI, 0.73-0.97]), p-tau181 ( R 2 , 0.88 [95% CI, 0.77-0.97]), and GFAP ( R 2 , 0.87 [95% CI, 0.76-0.97]). There was no correlation between posttreatment amyloid value and NfL ( R 2 , 0.03 [95% CI, 0.00-0.54]). Conclusions and Relevance The findings in this secondary analysis of a randomized clinical trial demonstrating a correlation between posttreatment amyloid plaque level and clinical benefit support amyloid plaque removal as the mechanism of action for donanemab treatment and the level of amyloid plaque as a potential surrogate biomarker in amyloid-targeting therapies. Trial Registration ClinicalTrials.gov Identifier: NCT04437511